CO2021001745A2 - Lípido catiónico - Google Patents
Lípido catiónicoInfo
- Publication number
- CO2021001745A2 CO2021001745A2 CONC2021/0001745A CO2021001745A CO2021001745A2 CO 2021001745 A2 CO2021001745 A2 CO 2021001745A2 CO 2021001745 A CO2021001745 A CO 2021001745A CO 2021001745 A2 CO2021001745 A2 CO 2021001745A2
- Authority
- CO
- Colombia
- Prior art keywords
- linear
- alkyl group
- cationic lipid
- integer
- group
- Prior art date
Links
- -1 Cationic lipid Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
RESUMEN La presente invención proporciona una técnica capaz de transferir un ingrediente activo, en particular, un ácido nucleico, a una célula con excelente eficiencia y un lípido catiónico para su uso en esta técnica, etc. El lípido catiónico de la presente invención es un compuesto representado por la fórmula (I) o su sal. n1 representa un número entero de 2 a 6, n2 representa un número entero de 0 a 2, n3 representa un número entero de 0 a 2, L representa -C(O)O- o -NHC(O)O-, Ra representa un grupo alquilo C5-13 lineal, un grupo alquenilo C13-17 lineal o un grupo alcadienilo C17 lineal, Rb representa un grupo alquilo C2-9 lineal, Rc representa un átomo de hidrógeno o un grupo alquilo C2-9 lineal, Rd representa un átomo de hidrógeno o un grupo alquilo C2-9 lineal, Re representa un grupo alquilo C2-9 lineal y Rf representa un grupo alquilo C2-9 lineal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018151583 | 2018-08-10 | ||
PCT/JP2019/031411 WO2020032184A1 (ja) | 2018-08-10 | 2019-08-08 | カチオン性脂質 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021001745A2 true CO2021001745A2 (es) | 2021-03-08 |
Family
ID=69414814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0001745A CO2021001745A2 (es) | 2018-08-10 | 2021-02-12 | Lípido catiónico |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220098142A1 (es) |
EP (1) | EP3835287A4 (es) |
JP (1) | JP7350749B2 (es) |
CN (2) | CN117304048A (es) |
AU (1) | AU2019317095B2 (es) |
BR (1) | BR112021002384B1 (es) |
CA (1) | CA3109207A1 (es) |
CO (1) | CO2021001745A2 (es) |
IL (1) | IL280620B2 (es) |
MX (1) | MX2021001654A (es) |
SG (1) | SG11202101356YA (es) |
TW (1) | TWI837161B (es) |
WO (1) | WO2020032184A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220145329A1 (en) * | 2018-08-10 | 2022-05-12 | Kyoto University | Method for transfection into cardiomyocytes using cationic lipid |
WO2022045334A1 (ja) | 2020-08-31 | 2022-03-03 | 武田薬品工業株式会社 | 推論装置、推論方法、推論プログラム、モデル生成方法、推論サービス提供システム、推論サービス提供方法及び推論サービス提供プログラム |
JPWO2023085299A1 (es) | 2021-11-10 | 2023-05-19 | ||
WO2023250197A2 (en) * | 2022-06-23 | 2023-12-28 | Turn Biotechnologies, Inc. | Lipid structures and compositions comprising same |
WO2024026308A2 (en) | 2022-07-29 | 2024-02-01 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE |
WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
WO2024128525A1 (ko) * | 2022-12-12 | 2024-06-20 | 한국과학기술연구원 | 신규한 지질 화합물 및 이를 포함하는 지질 나노입자 조성물 |
CN118108613A (zh) * | 2022-12-26 | 2024-05-31 | 北京新合睿恩生物医疗科技有限公司 | 一种阳离子脂质化合物及制备方法和应用、mRNA递送*** |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
WO2003102150A2 (en) | 2002-05-31 | 2003-12-11 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
KR101198715B1 (ko) | 2010-05-14 | 2012-11-13 | 한국생명공학연구원 | 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법 |
JP6305343B2 (ja) * | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質 |
SG11201700828PA (en) * | 2014-08-07 | 2017-03-30 | Takeda Pharmaceuticals Co | Cationic lipid |
TW201813632A (zh) * | 2016-09-28 | 2018-04-16 | 日商協和醱酵麒麟有限公司 | 含有核酸之脂質奈米粒子 |
JPWO2019131770A1 (ja) * | 2017-12-27 | 2020-12-24 | 武田薬品工業株式会社 | 核酸含有脂質ナノ粒子及びその用途 |
EP3733641B1 (en) * | 2017-12-28 | 2024-04-10 | Takeda Pharmaceutical Company Limited | Cationic lipids |
-
2019
- 2019-08-08 CA CA3109207A patent/CA3109207A1/en active Pending
- 2019-08-08 JP JP2020535882A patent/JP7350749B2/ja active Active
- 2019-08-08 SG SG11202101356YA patent/SG11202101356YA/en unknown
- 2019-08-08 US US17/267,179 patent/US20220098142A1/en active Pending
- 2019-08-08 EP EP19847498.3A patent/EP3835287A4/en active Pending
- 2019-08-08 WO PCT/JP2019/031411 patent/WO2020032184A1/ja unknown
- 2019-08-08 CN CN202311153246.8A patent/CN117304048A/zh active Pending
- 2019-08-08 IL IL280620A patent/IL280620B2/en unknown
- 2019-08-08 CN CN201980051986.6A patent/CN112533893B/zh active Active
- 2019-08-08 BR BR112021002384-4A patent/BR112021002384B1/pt active IP Right Grant
- 2019-08-08 AU AU2019317095A patent/AU2019317095B2/en active Active
- 2019-08-08 MX MX2021001654A patent/MX2021001654A/es unknown
- 2019-08-08 TW TW108128296A patent/TWI837161B/zh active
-
2021
- 2021-02-12 CO CONC2021/0001745A patent/CO2021001745A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021001654A (es) | 2021-05-12 |
TWI837161B (zh) | 2024-04-01 |
US20220098142A1 (en) | 2022-03-31 |
IL280620B1 (en) | 2024-02-01 |
SG11202101356YA (en) | 2021-03-30 |
AU2019317095A1 (en) | 2021-03-11 |
IL280620A (en) | 2021-03-25 |
JP7350749B2 (ja) | 2023-09-26 |
WO2020032184A1 (ja) | 2020-02-13 |
CN112533893B (zh) | 2023-12-22 |
AU2019317095B2 (en) | 2024-05-02 |
IL280620B2 (en) | 2024-06-01 |
JPWO2020032184A1 (ja) | 2021-08-26 |
BR112021002384B1 (pt) | 2024-01-23 |
BR112021002384A2 (pt) | 2021-05-11 |
CA3109207A1 (en) | 2020-02-13 |
CN112533893A (zh) | 2021-03-19 |
KR20210042089A (ko) | 2021-04-16 |
TW202021945A (zh) | 2020-06-16 |
CN117304048A (zh) | 2023-12-29 |
EP3835287A1 (en) | 2021-06-16 |
EP3835287A4 (en) | 2022-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021001745A2 (es) | Lípido catiónico | |
PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
AR101690A1 (es) | Composiciones tensioactivas acuosas | |
CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
SV2016005149A (es) | Polimorfo de los inhibidores de la syk | |
AR100233A1 (es) | Composición de limpieza | |
AR088551A1 (es) | Conjugados de hidromorfona con acido benzoico, derivados de acido benzoico y acido heteroarilcarboxilico; profarmacos, metodos de preparacion y uso de los mismos | |
CO6640270A2 (es) | Morfolinopirimidad y su uso en terapia | |
CR20140217A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
RS54623B1 (en) | ON POLYETHYLENE GLYCOL-BASED ADRENOMEDULIN PROTECTION AND ITS USE | |
CR20140195A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas | |
AR099238A1 (es) | Composiciones tensioactivas acuosas | |
AR089592A1 (es) | Sistemas de solventes de triamidas n-alquil-tiofosforicas y metodos de uso en aplicaciones agricolas | |
CR20140218A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii | |
DOP2014000285A (es) | Composicion herbicida que tiene actividad herbicida mejorada | |
AR117725A1 (es) | Composición acondicionadora para el cabello para deposición mejorada | |
CL2020003269A1 (es) | Composición para pozos | |
ECSP10010500A (es) | Composición pesticida en suspensión acuosa | |
DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
AR084948A1 (es) | Agente antifungico topico | |
BR112013025122A2 (pt) | uso cosmético de pelo menos um composto | |
MX2020004267A (es) | Sulfatos de alcoholes secundarios alcoxilados. | |
AR100466A1 (es) | Estabilización de formulaciones de emulsión de poliacrilamida | |
UY35228A (es) | Composiciones acuosas de cloquintocet-mexilo de temperatura estable | |
BR112013016637A2 (pt) | processo para a preparação de derivados de 3-alquil-sulfinilbenzoíla |